Warner Chilcott forecast disappoints market; EMA launches probe into Bayer's Diane 35;

@FiercePharma: Turns out, Vivus' slow launch of Qsymia may be best plan. News | Follow @FiercePharma

@EricPFierce: Sun tells Taro shareholders to forget it, cancels $685 million offer for Israeli generic drug player. Report | Follow @EricPFierce

@AlisonBFierce: Evidence of a link between GSK's Pandemrix and a spike in narcolepsy cases is putting AS03 under intense scrutiny. More | Follow @AlisonBFierce

> Specialty drugmaker Warner Chilcott ($WCRX) disappointed analysts today, saying generic competition for osteoporosis treatment Actonel will hurt sales this year. Story

> The European Medicines Agency has officially launched a safety review of Bayer's acne pill Diane 35 and its generic versions, after being asked by France to look more deeply at ties to blood clots. Story

> A Florida man has pleaded guilty to importing unapproved cancer drugs into the U.S. Release

> Swiss officials are taking steps to curb the influence of drug companies on doctors with new rules. Item

 @FierceMedDev: Ultrasound elastography eyed as cancer Dx method. Report | Follow @FierceMedDev

 @MarkHFierce: India is competing with the larger device companies by launching firms that make cheaper, quality alternatives. News | Follow @MarkHFierce

 @DamianFierce: LabCorp joins the list of diagnostics providers expecting Medicare cuts to take a bite out of 2013 revenue. Story | Follow @DamianFierce

> India's med device outfits beat multinationals on price. News

> Insulet ditches DexCom in diabetes collaboration. Article

Biotech News

 @FierceBiotech: Pfizer to lop off Asian research unit amid major R&D downsizing. Story | Follow @FierceBiotech

@RyanMFierce: Troubled biotech Tranzyme mulls potential sale after R&D face plants. More | Follow @RyanMFierce

> French biotech rapidly stuck on losing side of hep C revolution. News

> A new wave of biotechs takes shape in the U.K. Editor's Corner

> Oncolytics Biotech surges on lung cancer data. Story

And Finally... Merck ($MRK) Consumer Care Chief Bridgette Heller has been named Woman of the Year by the Healthcare Businesswomen's Association. More

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.